JOHN KIRKWOOD to Tumor Microenvironment
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Tumor Microenvironment.
Connection Strength
0.525
-
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
Score: 0.207
-
A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
Score: 0.077
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
Score: 0.027
-
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023 10; 11(10).
Score: 0.025
-
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol. 2023; 14:1171978.
Score: 0.025
-
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
Score: 0.023
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.021
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.021
-
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
Score: 0.018
-
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
Score: 0.018
-
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
Score: 0.017
-
Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017 Jun 01; 169(6):1130-1141.e11.
Score: 0.016
-
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44.
Score: 0.016
-
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15; 72(4):887-96.
Score: 0.011